Different classes of BRAF mutations are present in colorectal and other cancers. Non-V600 mutations are rare; however, their detection rate will increase as the use of next-generation sequencing ramps up quickly in clinical practice. Different biochemical signaling pathways are active in non-V600 BRAF-mutant cancers and may affect treatment response.See related article by Yaeger et al., p. 7089.
©2019 American Association for Cancer Research.